Imjudo (tremelimumab)
$32,344.23
This medicine requires a prescription. See “Prescription Guide”.
We can only help if the medicine is not available in your country. Learn more.
Imjudo (tremelimumab) is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated only in combination with Imfinzi (durvalumab), for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).
Imfinzi (durvalumab) is also available to order here.
Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) has been approved by the US Food, Drug and Administration (FDA) in October 2022 for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC), the most common type of liver cancer
Imjudo (tremelimumab)
What is Imjudo (tremelimumab) for?
Imjudo (tremelimumab) is a human monoclonal antibody (mAb), in combination with Imfinzi (durvalumab), also a human mAb, for treating adult patients with unresectable hepatocellular carcinoma (HCC). HCC is the most common type of liver cancer.
Where has Imjudo (tremelimumab) been approved?
Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) has been approved by the US Food, Drug and Administration (FDA) in October 2022 for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer
The prescribing information for Imjudo (tremelimumab) can be consulted here.
| 300 mg/15 mL (20 mg/mL) solution in a single-dose vial | 32,344.23 |
|---|
Be the first to review “Imjudo (tremelimumab)”
Related products
Colorectal Cancer
Reviews
There are no reviews yet.